HomeCompareBMY vs WAB

BMY vs WAB: Dividend Comparison 2026

BMY yields 4.17% · WAB yields 0.45%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WAB wins by $362.5K in total portfolio value· pulled ahead in Year 8
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
WAB
WAB
● Live price
0.45%
Share price
$237.37
Annual div
$1.06
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$483.0K
Annual income
$337,751.90
Full WAB calculator →

Portfolio growth — BMY vs WAB

📍 WAB pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYWAB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + WAB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
WAB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
WAB
Annual income on $10K today (after 15% tax)
$37.96/yr
After 10yr DRIP, annual income (after tax)
$287,089.12/yr
At 15% tax rate, WAB beats the other by $253,239.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + WAB for your $10,000?

BMY: 50%WAB: 50%
100% WAB50/50100% BMY
Portfolio after 10yr
$301.8K
Annual income
$188,787.78/yr
Blended yield
62.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on WAB right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
WAB
Analyst Ratings
21
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$277.80
+17.0% upside vs current
Range: $221.00 — $315.00
Altman Z
3.3
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
WAB buys
0
No recent congressional trades found for BMY or WAB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYWAB
Forward yield4.17%0.45%
Annual dividend / share$2.49$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%100%
Portfolio after 10y$120.5K$483.0K
Annual income after 10y$39,823.66$337,751.90
Total dividends collected$91.0K$450.4K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$62.73$277.80

Year-by-year: BMY vs WAB ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrWAB PortfolioWAB Income/yrGap
1$11,271$571.12$10,789$89.31+$482.00BMY
2$12,884$824.20$11,725$180.12+$1.2KBMY
3$14,993$1,206.32$12,911$365.85+$2.1KBMY
4$17,839$1,797.27$14,568$753.04+$3.3KBMY
5$21,826$2,738.11$17,176$1,588.17+$4.7KBMY
6$27,643$4,289.31$21,878$3,499.96+$5.8KBMY
7$36,534$6,955.64$31,743$8,332.99+$4.8KBMY
8← crossover$50,861$11,770.13$56,563$22,598.44$5.7KWAB
9$75,402$20,980.23$135,791$75,268.61$60.4KWAB
10$120,504$39,823.66$483,049$337,751.90$362.5KWAB

BMY vs WAB: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

WABStock

Westinghouse Air Brake Technologies Corporation provides technology-based equipment, systems, and services for the freight rail and passenger transit industries worldwide. It operates through two segments, Freight and Transit. The Freight segment manufactures and services components for new and existing freight cars and locomotives; builds new commuter locomotives; rebuilds freight locomotives; supplies railway electronics, positive train control equipment, signal design, and engineering services; and provides related heat exchange and cooling systems. It serves publicly traded railroads; leasing companies; manufacturers of original equipment, including locomotives and freight cars; and utilities. The Transit segment manufactures and services components for new and existing passenger transit vehicles, such as regional trains, high speed trains, subway cars, light-rail vehicles, and buses; refurbishes subway cars; and provides heating, ventilation, and air conditioning equipment, as well as doors for buses and subways. This segment serves public transit authorities and municipalities, leasing companies, and manufacturers of subway cars and buses. It also provides electronically controlled pneumatic braking products; railway electronics; freight car trucks; draft gears, couplers, and slack adjusters; air compressors and dryers; heat exchangers and cooling products; and track and switch products. In addition, the company offers railway braking equipment and related components; friction products; new switcher locomotives; transit locomotive and car overhaul services; and freight locomotive overhaul, modernizations, and refurbishment services. Further, it provides platform screen doors; pantographs; window assemblies; couplers; accessibility lifts and ramps for buses and subway cars; and traction motors. The company was founded in 1869 and is headquartered in Pittsburgh, Pennsylvania.

Full WAB Calculator →
📬

Get this BMY vs WAB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.